Let us not forget that recent board member Mark A. Schlossberg currently serves as Senior Vice President, General Counsel and Corporate Secretary of Impax Laboratories, Inc., where he is part of the senior management team responsible for the strategic direction and financial condition of the company. He leads the legal team and previously had responsibility for the healthcare compliance team. Prior to Impax, he served as Vice President, Associate General Counsel of Amgen Inc., where he led the legal department, and was responsible for corporate governance, securities law, licensing,(((( mergers and acquisitions, )))) global operations, and sales and marketing compliance. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc.
Now the question is, When Dr. Yu leaves will we be Out Of compliance with the NYSE again because of the departure of Dr.Yu , As was the case on Sept 22 with the appointments of 2 Directors ????
(( The appointment of Mr. Schlossberg and Mr. Lapointe as independent members of the Company's Board of Directors enables ImmunoCellular to regain compliance with the listing standards of the New York Stock Exchange MKT regarding the majority of independent directors' requirement as well as having at least three independent directors serving on the Audit Committee. ))
Sorry, Forgot to include this , "" Name and Address of Beneficial Owner. John S. Yu, M.D. Shares
Beneficially Owned 6,422,576 6.65 % ""
"" Includes 6,422,576 shares of our common stock underlying stock options that are exercisable within 60 days of September 15, 2015.""
You may never know that answer, IMO, If they asked him to resign, It would have taken effect immediately, On the other hand he was Founder, Chairman, Chief Scientific Officer and Corp. Sec. and made $220K yearly, CEO made $533K, So he was not the top dog in this show.
From DEF 14A , Name and Address of Beneficial Owner. John S. Yu, M.D. Shares
Beneficially Owned 6,422,576 6.65 %
If he starts selling those shares, You'll get your answer
"" Dr. Yu will provide consulting services to the Company, including supporting the execution of the phase 3 clinical trial of ICT-107 and assisting with the evaluation and acquisition of outside technology. Dr. Yu will receive a fee of $11,103 per month. The term of the Agreement expires on December 31, 2015, ""
It seems Dr. Yu is staying just long enough to see the execution of the phase 3 clinical trial of ICT-107, Which by the way is due any week now, This news was known by the Company on Oct 1st the day Dr. Yu filed his form 4's.
The Company also filed their DEF 14A the other day and are increasing their authorized number of shares of common stock from 149,000,000 to 249,000,000, From the DEF 14A "" establishing strategic relationships with other companies; expanding the Company’s business or product lines through the acquisition of other businesses or products; and other purposes. "" They have mentioned a few times in past filings that they are looking at the " evaluation and acquisition of outside technology " and in this filing they mention the same line and say " Dr. Yu will assist with the evaluation and acquisition of outside technology " Seeing that he's leaving by Dec. 31st 2015, That'll give you food for thought !!!!
So true, So true, he keep on buying small cap stocks without doing DD, He'll find out soon that he's made a bad trade in a bad stock, And find that the stock has fallen and it cant get up.
I would much rather be in a stock like this that has cash and grant money for at least 3 years and finish Ph3, No Debt, Nice pipeline and plenty of support. Good Luck Robert, You'll need it.
Sentiment: Strong Buy
To be honest, This price has more to do with it being under .50, It can be highly manipulated at this price, I wouldn't pay to much attention to it if you already own the stock. They have cash and grant money of around $50M , Enough for them to complete Ph. 3 Trials, And that may also be part of the problem, Ph 3 will take years and the shorts know that, Hence the current share price. Good Luck
I know you've said you were at one time a market maker, believe me , this was a play by shorts and the market maker took full advantage of the situation, this was a bear raid and the MM let it happen for obvious reasons, he'll be pumping the price up at some point and dump his position. As for someone knowing something, If they do know something, they know that this is fully funded for at least 3 - 4 years, no problems there, full funding for Ph 3 to completion, DELISTING issue solved, So what's the problem, Daytraders that's what, they panicked on Friday because they haven't done their DD and the bear raid came in and finished them off , With the help of the MM, you've got to have strong hands and know what you're buying, give it time, I think this time is a charm.
You can be darn sure they'll be selling those shares on monday for a nice profit, rinse and repeat
You guys just got bent over
Im Loaded, Dont care what it does between now and Ph3 News, Good Luck To All, Lots of weak hands here, But I do thank them.
Yup, Pipeline is impressive to say the least, Will start p3 very soon on ict 107, Im very surprised at the low price, Cash on hand and Grant cash ='s the market cap , Thats totally discounting the pipeline, Everything is coming together, Delisting issue was taken care of yesterday, Funding enough to complete P3, Seems they have worked out the problems they had in Dec. 2013 with ICT 107 and we have reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma, All thats left is moving the share price higher, G/L All
But in my opinion, Theres money to be made here on the long side if you can come close to the low, Im waiting
They are cherry picking the winners out of the trials and that is the key here.
$$$$$As we evaluate our next steps, it is necessary to conserve cash while we continue our analysis of the VTI-208 clinical trial data to possibly support the design and implementation of a new clinical trial to confirm what we believe to be promising pre-defined subset and post hoc analyses,$$$$$
said Terry Winters, Ph.D., Chief Executive Officer and Co-Chairman of Vital Therapies. "This has been a difficult process, but I want to thank each and every one of our departing employees for their hard work, passion and dedication. We will not forget their contributions and we wish them well."
The Company continues to analyze the entire VTI-208 data set in order to determine the potential next steps in clinical development. In particular, the company is exploring the design of a new phase 3 clinical trial, which may limit subjects based on both Model for End-Stage Liver Disease (MELD) score and age. The Company will provide periodic updates on material developments.